Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing

In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including: - CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancer - Early-phase efficacy data with investigational CDH6-directed ADCs, including raludotatug deruxtecan (R-DXd) and CUSP06, and an ongoing phase III trial of R-DXd - Safety considerations with CDH6-directed ADCs, including cytopenias, gastrointestinal toxicities, fatigue, and interstitial lung disease/pneumonitis - Considerations for sequencing ADCs, including the potential impact of target expression, payload class, and mechanisms of resistance **Presenters:** **BJ Rimel, MD** Division Chief, Gynecologic Oncology Professor, Department of OB/GYN University of Washington Clinical Director of Gynecologic Oncology Fred Hutchinson Cancer Center Seattle, Washington **Elizabeth Lee, MD** Division of Gynecologic Oncology Center for Cancer Therapeutic Innovation Department of Medical Oncology Dana-Farber Cancer Institute Boston, Massachusetts **Link to full program:**  https://bit.ly/3SqCAZ6 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.